Expression of redox pathway enzymes in human prostatic tissue

Analytical and Quantitative Cytology and Histology

Volumn 31, Issue 6, 2009, Pages 367-374

  Valdman, Alexander ^a   Häggarth, Lars ^a,b   Cheng, Liang ^d   Lopez Beltran, Antonio ^e   Montironi, Rodolfo ^f   Ekman, Peter ^c   Egevad, Lars ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b St Gran's Hospital   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Facultad de Medicina de Córdoba   (Spain)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Cancer, prostate; Immunohistochemistry; Neoplasia, prostatic intraepithelial; Peroxiredoxin; Thioredoxin; Thioredoxin reductase; Tissue microarray

Indexed keywords

PEROXIREDOXIN; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; ANIMALS; ATROPHY; DISEASE-FREE SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIDATION-REDUCTION; PEROXIREDOXINS; PROSTATE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; THIOREDOXIN REDUCTASE 2; THIOREDOXINS; TISSUE ARRAY ANALYSIS;

EID: 74549225085     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Arner ES, Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000;267:6102-6109
2. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL: Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 2006;281:13005-13008
3. Arner ES, Holmgren A: The thioredoxin system in cancer. Semin Cancer Biol 2006;16:420-426
4. Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, Orrenius S: Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 2005;327:774-779
5. Ebert R, Ulmer M, Zeck S, Meissner-Weigl J, Schneider D, Stopper H, Schupp N, Kassem M, Jakob F: Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. Stem Cells 2006;24:1226-1235
6. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA: Electrophilic prostaglandins and lipid aldehydes repress redoxsensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 2003;278:745-750
7. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, Ma J: A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696-703
8. Klein EA: Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 2004;1031:234-241
9. Kumar S, Björnstedt M, Holmgren A: Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem 1992;207:435-439
10. Streicher KL, Sylte MJ, Johnson SE, Sordillo LM: Thioredoxin reductase regulates angiogenesis by increasing endothelial cell-derived vascular endothelial growth factor. Nutr Cancer 2004;50:221-231
11. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM: The thioredoxin-thioredoxin reductase system: Over-expression in human cancer. Anticancer Res 2003;23:2425-2433
12. Haapasalo H, Kyläniemi M, Paunul N, Kinnula VL, Soini Y: Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol 2003;13:155-164
13. Powis G, Kirkpatrick DL: Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 2007;7:392-397
14. Lexander H, Palmberg C, Auer G, Hellström M, Franzén B, Jörnvall H, Egevad L: Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 2005;27:263-272
15. Lexander H, Franzén B, Hirschberg D, Becker S, Hellström M, Bergman T, Jörnvall H, Auer G, Egevad L: Differential protein expression in anatomical zones of the prostate. Proteomics 2005;5:2570-2576
16. Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979;59:527-605
17. Han YH, Kwon JH, Yu DY, Moon EY: Inhibitory effect of peroxiredoxin II (Prx II) on Ras-ERK-NFkappaB pathway in mouse embryonic fibroblast (MEF) senescence. Free Radic Res 2006;40:1182-1189
18. Chang R, Wang E: Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem 2007;100:267-278
19. Bae JY, Ahn SJ, Han W, Noh DY: Peroxiredoxin I and II inhibit H(2)O(2)-induced cell death in MCF-7 cell lines. J Cell Biochem 2007;101:1038-1045
20. Yuan J, Murrell GA, Trickett A, Landtmeters M, Knoops B, Wang MX: Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss of cellular function during oxidative stress. Biochim Biophys Acta 2004;1693:37-45
21. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG: Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 1998;273:6297-6302
22. Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 2001;357:539-545
23. Kusmartsev S, Gabrilovich DI: Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002;51:293-298
24. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V: Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72
25. Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC: Mechanisms of tumor evasion. Cancer Treat Res 2005;123:61-88
26. Lechner M, Lirk P, Rieder J: Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol 2005;15:277-289
27. Baniyash M: TCR zeta-chain downregulation: Curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004;4:675-687
28. Egevad L: Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol 2008;30:190-198
29. Egevad L: Recent trends in Gleason grading of prostate cancer: II. Prognosis, reproducibility and reporting. Anal Quant Cytol Histol 2008;30:254-260
30. Jonmarker S, Glaessgen A, Culp WD, Pisa P, Lewensohn R, Ekman P, Valdman A, Egevad L: Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS 2008;116:491-498
31. Rosenblatt R, Valdman A, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, Egevad L: Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia. Anal Quant Cytol Histol 2009;31:137-142